Market Alert: Trump-Xi APEC Summit a Critical Test for Global Trade Stability
Artrya Limited (ASX: AYA), a medical technology company advancing its AI-driven Salix cloud platform for coronary artery disease diagnosis and management, has successfully completed Tranche 2 of its share placement. The company issued 7,175,588 fully paid ordinary shares at AU$2.05 per share, raising approximately AU$14.7 million before costs. This follows the initial announcement made on 8 September 2025, marking the full completion of the placement process.
The funds raised are expected to bolster Artrya’s commercialisation efforts, accelerate product development, and support strategic growth opportunities. An Appendix 2A will be lodged for the quotation of new shares, along with a cleansing statement for compliance purposes. This placement reinforces investor confidence in Artrya’s innovative AI technology and its mission to transform cardiovascular disease detection and treatment at the point of care.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
